Introduction to Anthem Biosciences IPO
Anthem Biosciences Limited is coming up with its Initial Public Offering (IPO) which opens for subscription on July 14, 2025 and closes on July 16, 2025. The IPO is entirely an Offer for Sale (OFS) of 5.96 crore shares, aggregating up to ₹ 3,395 crore. The company will not receive any proceeds from this issue. This IPO is drawing attention due to its strong presence in the Contract Research, Development, and Manufacturing Organization (CRDMO) space. In this article we would analyse and review Anthem Biosciences IPO, Details, IPO Dates, Risk Factors, Reasons to invest, GMP, Valuations and provide our view about this IPO.
About Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences is a technology-driven CRDMO offering end-to-end solutions across drug discovery, development, and manufacturing. It provides specialized fermentation-based APIs, probiotics, enzymes, peptides, and biosimilars to global clients in over 44 countries.
The company had 196 active projects as of September 30, 2024, and a strong customer base including over 550 clients, ranging from emerging biotech to large pharma companies.
Competitive Strengths
- Fully integrated CRDMO with presence across the drug life cycle.
- Focus on innovation with strong patent portfolio (7 overseas, 1 India, 24 pending).
- Strong global client base across 44+ countries.
- Experienced management and robust R&D team (600+ scientists).
- Diversified revenue from CRDMO and specialty ingredients businesses.
Anthem Biosciences IPO Issue Details
- IPO Opening Date: July 14, 2025
- IPO Closing Date: July 16, 2025
- Listing Date: July 21, 2025 (Tentative)
- Price Band: ₹ 540 – ₹ 570 per share
- Lot Size: 26 shares
- Minimum Investment: ₹ 14,820
- Employee Discount: ₹ 50/share
- Total Issue Size: ₹ 3,395 crore (OFS only)
- Listing At: BSE and NSE
Financials of Anthem Biosciences
| Particulars | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue (Cr) | 1,133.99 | 1,483.07 | 1,930.29 |
| PAT (Cr) | 385.19 | 367.31 | 451.26 |
| EBITDA (Cr) | 446.05 | 519.96 | 683.78 |
| Net Worth (Cr) | 1,740.67 | 1,924.66 | 2,409.86 |
| ROE | – | – | 20.82% |
| ROCE | – | – | 26.88% |
| PAT Margin | – | – | 23.38% |
| EBITDA Margin | – | – | 36.81% |
| Debt/Equity | – | – | 0.05 |
P/E Ratio and Peer Comparison
- EPS (FY25): ₹ 8.07
- P/E at upper price band (₹ 570): ~70.62x
Peers: Most listed CRDMO companies in India trade at high P/E due to limited supply and global demand. However, a P/E over 70x for this IPO suggests aggressive pricing.
Objects of the Issue
This IPO is a complete Offer for Sale, and no proceeds will go to the company. The entire amount will be received by selling shareholders.
Grey Market Premium (GMP) of Anthem Biosciences IPO
As of latest updates, the GMP is around ₹ 110-130, indicating a potential listing gain of 20-23% over the upper band price.
Reasons to Invest in Anthem Biosciences IPO
- One of India’s leading CRDMO players.
- Strong revenue and profit growth.
- Low debt (D/E of 0.05), high ROE and ROCE.
- Diversified global client base.
- Likely listing gains as per current GMP.
Risk Factors
- Entirely an OFS; company won’t receive funds.
- Premium valuation with P/E ~70x.
- High dependency on international clients.
- Regulatory risks related to pharma manufacturing.
- No long-term guidance provided.
How to Apply for Anthem Biosciences IPO?
Investors can apply via:
- Net banking using ASBA (under IPO section)
- UPI through broker platforms like Zerodha, Groww, Upstox
Ensure UPI mandate is approved before 5 PM on July 16, 2025.
Conclusion: Should you Subscribe to Anthem Biosciences IPO or Avoid?
Anthem Biosciences has shown strong financial growth and commands a niche position in the CRDMO space. While the valuation appears premium, the solid fundamentals and strong GMP suggest positive listing potential. High-risk investors with long-term view can Subscribe to this IPO. Conservative investors may wait for post-listing opportunities.
FAQs on Anthem Biosciences IPO
- What is the Anthem Biosciences IPO date?
- The IPO opens on July 14, 2025, and closes on July 16, 2025.
- What is the Anthem Biosciences IPO price band?
- The price band is ₹ 540 to ₹ 570 per share.
- What is the minimum lot size for Anthem Biosciences IPO?
- Minimum lot is 26 shares, which amounts to ₹ 14,820.
- What is the GMP of Anthem Biosciences IPO?
- As per the latest, GMP is around ₹ 110-130.
- Is Anthem Biosciences IPO good for investment?
- It is suitable for high-risk investors seeking long-term growth in the biotech and pharma space.
- How much is the IPO size and structure?
- IPO size is ₹ 3,395 crore, and it is a 100% Offer for Sale.
- When will Anthem Biosciences IPO be listed?
- Tentative listing date is July 21, 2025 on BSE and NSE.
Disclaimer: This article is for informational purposes only and not a recommendation or solicitation to buy or sell any securities. The IPO review is based on information available in the Red Herring Prospectus (RHP) and other reliable sources at the time of writing. Readers are advised to consult their financial advisor before making any investment decision. Myinvestmentideas.com or the author is not responsible for any losses incurred based on this information.
- 10 Mutual Funds Outperformed in Last 1 Year with 37% to 82% Returns - August 12, 2025
- Regaal Resources IPO Review – Dates, Price, GMP, Analysis – Should You Invest or Avoid? - August 11, 2025
- 10 Mutual Funds That Crashed the Most in the Last 6 Months in 2025 - August 8, 2025
Discover more from Myinvestmentideas.com
Subscribe to get the latest posts sent to your email.
Good Analysis report , thanks a lot sir